In vitro cytotoxicity of the LDE: daunorubicin complex in acute myelogenous leukemia blast cells
AUTOR(ES)
Dorlhiac-Llacer, P.E., Marquezini, M.V., Toffoletto, O., Carneiro, R.C.G., Maranhão, R.C., Chamone, D.A.F.
FONTE
Brazilian Journal of Medical and Biological Research
DATA DE PUBLICAÇÃO
2001-10
RESUMO
Acute myelogenous leukemia (AML) blast cells show high-affinity degradation of low-density lipoprotein (LDL), suggesting an increased expression of cellular LDL receptors. LDE is a lipid microemulsion easily synthesized in vitro which is known to mimic the metabolic pathway of LDL. We used LDE as a carrier for daunorubicin and assayed the cytotoxicity of the complex using AML blast cells since RT-PCR analysis showed that AML cells express LDL receptor mRNA. The LDE:daunorubicin complex killed 46.7% of blast cells and 20.2% of normal bone marrow cells (P<0.001; Student t-test). Moreover, this complex destroyed AML blast cells as efficiently as free daunorubicin. Thus, LDE might be a suitable carrier of chemotherapeutic agents targeting these drugs to neoplastic cells and protecting normal tissues.
Documentos Relacionados
- Blast crisis in a murine model of chronic myelogenous leukemia.
- Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro.
- In vitro evaluation of triazenes: DNA cleavage, antibacterial activity and cytotoxicity against acute myeloid leukemia cells
- p53 in chronic myelogenous leukemia in acute phase.
- Pretreatment of cytokinetics in acute myelogenous leukemia. Age-related prognostic implications.